8 力平之研究-Dais-Field-Accord--完成.pptVIP

The ACCORD Lipid results are consistent with other fibrate trials, including FIELD. In these trials, fibrate treatment reduced cardiovascular risk to a greater extent in patients with elevated triglycerides and low HDL-C as compared to the overall population. ACCORD Lipid provides further evidence of the effectiveness of 非诺贝特 for this subgroup, and extends it by showing efficacy on top of a statin. ACCORD血脂研究结果也为目前的指南提供了进一步的支持。这些指南推荐在甘油三酯200 mg/dL或HDL-C低的情况下在他汀类治疗中增加贝特类。 There was no difference in treatment effect in any other pre-specified subgroup with the exception of gender. A significant interaction was seen that suggested a benefit of 非诺贝特 for men and a trend toward harm for women. However, no such finding was seen in the FIELD study. Furthermore, a gender difference was not seen in the subgroup of patients with elevated triglycerides and low HDL-C. Slide * In the ACCORD Lipid trial, long-term treatment with the combination of 辛伐他汀 and 非诺贝特 was well tolerated. Over the 5 years of the trial, overall rates of adverse events were low and did not significantly differ between treatment groups. The incidence of myositis or rhabdomyolysis was identical in the combination therapy and monotherapy groups. This finding is consistent with FIELD and other trials showing no increased risk of muscle adverse events with 非诺贝特-statin combination therapy compared to either monotherapy. There were also no major differences in biological abnormalities between treatments. A higher percentage of patients treated with 非诺贝特 had elevated serum creatinine, a known reaction to 非诺贝特 treatment. A substudy of the FIELD trial has shown that this increase is fully and rapidly reversible, and is not a sign of kidney impairment. Slide * Patients with type 2 diabetes face a substantially higher risk of cardiovascular disease and death as compared to non-diabetic patients. The number of people with type 2 diabetes is rising worldwide and will continue to rise for the foreseeable future. P